CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Prevalence, risk factors, and management of asthma in China: a national cross-sectional study 期刊论文
LANCET, 2019, 卷号: 394, 期号: 10196
作者:  Huang, Kewu;  Yang, Ting;  Xu, Jianying;  Yang, Lan;  Zhao, Jianping
收藏  |  浏览/下载：65/0  |  提交时间：2019/12/05
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial 期刊论文
LANCET ONCOLOGY, 2019, 卷号: 20, 期号: 6
作者:  Jiang, Zefei;  Li, Wei;  Hu, Xichun;  Zhang, Qingyuan;  Sun, Tao
收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05
Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study 会议论文
作者:  Xu, Rui-hua;  Wang, Fenghua;  Xu, Nong;  Shen, Lin;  Dai, Guanghai
收藏  |  浏览/下载：13/0  |  提交时间：2019/12/05
Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study 会议论文
作者:  Xu, Rui-hua;  Wang, Fenghua;  Shi, Jianhua;  Feng, Ji Feng;  Shen, Lin
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study 期刊论文
LANCET, 2018, 卷号: 391, 期号: 10131
作者:  Wang, Chen;  Xu, Jianying;  Yang, Lan;  Xu, Yongjian;  Zhang, Xiangyan
收藏  |  浏览/下载：41/0  |  提交时间：2019/12/05
Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study 会议论文
作者:  Xu, Ruihua;  Wang, Fenghua;  Li, Qi;  Shi, Jianhua;  Shen, Lin
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial 期刊论文
LANCET ONCOLOGY, 2017, 卷号: 18, 期号: 3
作者:  Zhang, Pin;  Sun, Tao;  Zhang, Qingyuan;  Yuan, Zhongyu;  Jiang, Zefei
收藏  |  浏览/下载：19/0  |  提交时间：2019/12/05
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+advanced breast cancer in BOLERO-1 期刊论文
BREAST CANCER RESEARCH, 2017, 卷号: 19
作者:  Toi, Masakazu;  Shao, Zhimin;  Hurvitz, Sara;  Tseng, Ling-Ming;  Zhang, Qingyuan
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China 期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 35
作者:  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li;  Feng, Jifeng
收藏  |  浏览/下载：64/0  |  提交时间：2019/12/05
A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the 会议论文
作者:  Jiang, Zefei;  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li
收藏  |  浏览/下载：59/0  |  提交时间：2019/12/13

©版权所有 ©2017 CSpace - Powered by CSpace